What’s next for Viking Therapeutics? Here’s how the company can scale up. - MarketWatch
1. VKTX stock rose 3% after positive Oppenheimer analysis. 2. Recent meetings discussed obesity drug VK2735's potential scaling. 3. VK2735 shows promising early data with significant weight loss. 4. All analysts have buy ratings on VKTX, indicating high confidence. 5. Oppenheimer anticipates strong future performance from VKTX's pipeline.